Related Experiment Video
Updated: May 24, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
SLC16A13 Downregulation Contributes to Apoptosis Induction in A549 Lung Cancer Cell Line
Aysan Zeinolabedini1, Habib Zarredar1, Venus Zafari2
1Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Background:
Lung cancer, a lethal type of malignancy in the world, has different pathological subcategories, among which NSCLC is the most common form. The complex pathogenesis of this disease has caused its treatment in advanced stages to be accompanied by many problems. Recently, the genes involved in metabolism, especially those coding for membrane transporter proteins (the solute carrier) have received attention in cancer studies. The Solute Carrier Family 16 Member 1 (SLC16A) is membrane transporters the role of which in the promotion of cancer has been revealed in recent years. This study aimed to examine the effect of SLC16A13 low expression in A549 lung cancer cells, focusing on its role in key cellular processes such as viability, proliferation, and apoptosis. By targeting SLC16A13, a critical member of the solute carrier family implicated in cancer metabolism, the study search for to uncover molecular mechanisms that could inform novel therapeutic strategies for non-small cell lung cancer.
Methods:
At first, the A549 lung cancer cell line was cultured in a standard medium, and then specific synthetic SLC16A13 sh-RNA was transfected into the A549 cell line to suppress the expression of this membrane transporter. We used MTT and flow cytometry tests to investigate the effect of reducing the expression of SLC16A13 on the process of cell viability and apoptosis. Also, the change of gene expression was analyzed by Real-Time PCR.
Results:
In the present study, the reduction of SLC16A13 gene expression caused an increase in the apoptosis rate and reduced cell viability in lung cancer cells. Also, SLC16A13 suppression may induce apoptosis pathway by upregulating Bax, Caspase-3, and Caspase-9 expression while downregulation Bcl-2 expression. Besides, it was shown that SLC16A13 downregulation couldn't affect E-cadherin expression.
Conclusion:
SLC16A13 may a promising target to increase cell death in lung cancer cells by inducing apoptosis pathways.
Insights
Reducing Solute Carrier Family 16 Member 1 (SLC16A13) expression in lung cancer cells boosts apoptosis and lowers viability. This suggests SLC16A13 is a potential therapeutic target for non-small cell lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Solute carrier (SLC) proteins, involved in cellular metabolism, are increasingly recognized for their roles in cancer.
- The Solute Carrier Family 16 Member 1 (SLC16A13) transporter has emerged as a potential player in cancer promotion.
Purpose of the Study:
- To investigate the functional impact of reduced SLC16A13 expression in A549 lung cancer cells.
- To explore the role of SLC16A13 in regulating cancer cell viability, proliferation, and apoptosis.
- To identify potential therapeutic strategies for NSCLC by targeting SLC16A13.
Main Methods:
- Culturing A549 lung cancer cell line.
- Transfecting cells with SLC16A13 sh-RNA to suppress gene expression.
- Assessing cell viability using MTT assays.
- Analyzing apoptosis rates via flow cytometry.
- Quantifying gene expression changes with Real-Time PCR.
Main Results:
- Suppression of SLC16A13 significantly increased apoptosis rates in lung cancer cells.
- Reduced SLC16A13 expression led to decreased cancer cell viability.
- SLC16A13 downregulation upregulated pro-apoptotic markers (Bax, Caspase-3, Caspase-9) and downregulated anti-apoptotic marker (Bcl-2).
- E-cadherin expression remained unaffected by SLC16A13 suppression.
Conclusions:
- SLC16A13 plays a role in regulating apoptosis and viability in lung cancer cells.
- Targeting SLC16A13 presents a promising strategy for inducing cell death in NSCLC.
- Modulating SLC16A13 expression could offer novel therapeutic avenues for lung cancer treatment.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...